Enhancing transparency and efficiency in reporting industry-sponsored clinical research: Report from the Medical Publishing Insights and Practices initiative

International Journal of Clinical Practice

Volumn 64, Issue 8, 2010, Pages 1028-1033

  Clark, J ^a   Gonzalez, J ^b   Mansi, B ^c   Miller, C ^c   Mooney, L A ^d   Mosdell, K ^a   Richards, D ^e   Schreiweis, M ^a   Weigel, A ^f   Wager, E ^g  

^a AMGEN INC   (United States)

^b ASTRAZENECA   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

^d PFIZER INC   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

^f International Society for Medical Publication Professionals   (United States)

^g Sideview   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; CLINICAL RESEARCH; DRUG INDUSTRY; FUNDING; MEDICAL LITERATURE; PEER REVIEW; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLISHING; QUALITY CONTROL; REVIEW; TRUST;

CLINICAL TRIALS AS TOPIC; DISCLOSURE; DRUG INDUSTRY; INTERPROFESSIONAL RELATIONS; PEER REVIEW, RESEARCH; PERIODICALS AS TOPIC; RESEARCH SUPPORT AS TOPIC; TRUST;

EID: 77953854183     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02416.x     Document Type: Review

References (15)

1. Drug company to make its trial results public. BMJ 2004 329 : 366.
2. Anon. National Library of Medicine Fact Sheet: Medline. http://www.nlm.nih.gov/pubs/factsheets/medline.html.
3. Wager E. FDAAA Legislation: Global Implications for Clinical Trial Reporting and Publication Planning. 2008. http://www.keywordpharma.com, Keyword Pharma. Expert Reviews.
4. Groves T, Schroter S. BMJ pico for original research in the print BMJ. BMJ 2009 339 : b3168.
5. ICMJE Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication. http://www.icmje.org/.
6. Anon. Is the BMJ the Right Journal for my Research Article? http://resources.bmj.com/bmj/authors/authors/checklists-forms/ is-bmj-the-right-journal-for-my-research-article.
7. PLoS Editors. Ghostwriting: the dirty little secret of medical publishing that just got bigger. PLoS Med 2009 6 : e1000156.
8. Sismondo S. Ghosts in the machine: publication planning in the medical sciences. Social Studies of Science 2009 39 : 171.
9. Lo B, Field MJ (eds.). Conflict of Interest in Medical Research, Education and Practice (Institute of Medicine).
10. Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies. Curr Med Research Opinion 2003 19 : 149 154. (Pubitemid 36612997)
11. Graf C, Battisti WP, Bridges D et al. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ 2009 339 : b4330.
12. PhRMA Principles on Conduct of Clinical Trials and Communication of Clinical Trial Results. http://www.phrma.org.
13. Jacobs A, Wager E. EMWA guidelines on the role of medical writers in developing peer-reviewed publications. Curr Med Res Opin 2005 21 : 317 321.
14. Norris R, Bowman A, Fagan JM et al. International Society for Medical Publication Professionals (ISMPP) position statement: the role of the professional medical writer. Curr Med Research Opinion 2007 23 : 1837 1840.
15. WAME Policy Statement: Ghost Writing Initiated by Commercial Companies. http://www.wame.org/resources/policies#ghost.